<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04696458</url>
  </required_header>
  <id_info>
    <org_study_id>IP</org_study_id>
    <nct_id>NCT04696458</nct_id>
  </id_info>
  <brief_title>Effects of a Multispecies Probiotic on Migraine</brief_title>
  <official_title>Effects of a Multispecies Probiotic on Migraine: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Scripps Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kaneka Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Scripps Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The prevalence of migraine is higher in female patients with various intestinal diseases. An&#xD;
      explanation could be that migraine is caused by a leaky gut, defined by increased intestinal&#xD;
      permeability that permits particles to pass through the gastrointestinal wall. Probiotics,&#xD;
      may be able to improve intestinal barrier function.&#xD;
&#xD;
      OBJECTIVE: To test whether probiotics, as adjucnt therapy, can reduce incidence and severity&#xD;
      of migraine attacks by reducing intestinal permeability.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Given the significant unmet need for improved therapies that address migraine disorders and&#xD;
      concurrent irritable bowel syndrome (IBS), this study seeks to investigate the impact of&#xD;
      probiotics on the sequelae of symptoms associated with both migraine and IBS.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2021</start_date>
  <completion_date type="Anticipated">April 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in Migraine-induced Disability as measured by the Migraine Induced Disability Assessment Score (MIDAS) total score</measure>
    <time_frame>Change day 0 to week 12</time_frame>
    <description>This survey measures headache frequency, disability, severity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improved Quality of Life (QoL) and reduced depressive symptoms (per Patient Health Questionnaire (PHQ-9))</measure>
    <time_frame>Change day 0 to week 12</time_frame>
    <description>Survey used to assess depressive symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduced severity of Gastrointestinal (GI) symptoms (per Irritable Bowel Syndrome Severity Scoring System (IBS -SSS))</measure>
    <time_frame>Change day 0 to week 12</time_frame>
    <description>Survey used to assess IBS symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduced generalized anxiety (per Generalized Anxiety Disorder (GAD-7))</measure>
    <time_frame>Change day 0 to week 12</time_frame>
    <description>Survey used to assess anxiety symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduce headache parameters (headache episodes, headache days, intensity, duration) based on MIDAS subcomponents and journal/diary</measure>
    <time_frame>Change day 0 to week 12</time_frame>
    <description>Survey used to assess migraine treatments symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in acute medication requirements</measure>
    <time_frame>Change day 0 to week 12</time_frame>
    <description>Survey used to assess medication requirements</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Migraine</condition>
  <condition>Irritable Bowel Syndrome</condition>
  <condition>Headache, Migraine</condition>
  <arm_group>
    <arm_group_label>EXPERIMENTAL PROBIOTIC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 Multistrain Probiotic Capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 Identical Placebo Capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lactobacillus plantarum (CECT7484 and CECT7485)/ Pediococcus acidilactici (CECT7483)</intervention_name>
    <description>Probiotic Capsules in blister packets of capsules containing the probiotic intervention contain a combination of three strains of lactic acid bacteria: two Lactobacillus plantarum (CECT7484 and CECT7485) and one Pediococcus acidilactici (CECT7483).</description>
    <arm_group_label>EXPERIMENTAL PROBIOTIC</arm_group_label>
    <other_name>Placebo Comparator: Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Comparator: Placebo</intervention_name>
    <description>Placebo Capsules in blister packets of capsules containing the inert (controlled) non-interventional treatment.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>inert placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Episodic migraine diagnosis for a minimum of 1 year (12-months)&#xD;
&#xD;
          -  Between 3-12 migraine episodes /month&#xD;
&#xD;
          -  Comorbid, symptomatic, irritable bowel syndrome during the screening period&#xD;
&#xD;
          -  On a steady treatment regimen: preventative and acute migraine medications and&#xD;
             therapies unchanged over the last 6 months&#xD;
&#xD;
          -  Access to Scripps Center for Integrative Medicine&#xD;
&#xD;
          -  Access to smartphone or computer to complete electronic surveys&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other GI or hepatic diagnoses (Inflammatory Bowel Disease (IBD), Small Intestinal&#xD;
             Bacterial Overgrowth (SIBO), Non-Alcoholic Fatty Liver Disease (NAFLD), elevated Liver&#xD;
             Function Tests (LFTs) within the last 6 months)&#xD;
&#xD;
          -  Prior GI surgery&#xD;
&#xD;
          -  Prior GI infection in the previous 3-months&#xD;
&#xD;
          -  Antibiotic treatment in previous last 3 months&#xD;
&#xD;
          -  Diagnosed Autoimmune disease&#xD;
&#xD;
          -  Current corticosteroids use&#xD;
&#xD;
          -  Morbid obesity (BMI &gt;40)&#xD;
&#xD;
          -  Took Probiotics or Probiotic-containing supplements or therapy in the previous&#xD;
             3-months&#xD;
&#xD;
          -  Diagnosis of post-traumatic headache or cervicogenic headache&#xD;
&#xD;
          -  Pregnancy or plans to become pregnant during study participation&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Megan Sweeney, MPH</last_name>
    <role>Study Chair</role>
    <affiliation>Scripps Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Heather Catchpole, MS</last_name>
    <role>Study Director</role>
    <affiliation>Scripps Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robert Bonakdar, MD</last_name>
    <phone>858-554-3300</phone>
    <email>bonakdar.robert@scrippshealth.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Heather Catchpole, MS</last_name>
    <phone>858-554-3360</phone>
    <email>catchpole.heather@scrippshealth.org</email>
  </overall_contact_backup>
  <reference>
    <citation>Arzani M, Jahromi SR, Ghorbani Z, Vahabizad F, Martelletti P, Ghaemi A, Sacco S, Togha M; School of Advanced Studies of the European Headache Federation (EHF-SAS). Gut-brain Axis and migraine headache: a comprehensive review. J Headache Pain. 2020 Feb 13;21(1):15. doi: 10.1186/s10194-020-1078-9. Review.</citation>
    <PMID>32054443</PMID>
  </reference>
  <reference>
    <citation>Dai YJ, Wang HY, Wang XJ, Kaye AD, Sun YH. Potential Beneficial Effects of Probiotics on Human Migraine Headache: A Literature Review. Pain Physician. 2017 Feb;20(2):E251-E255. Review.</citation>
    <PMID>28158162</PMID>
  </reference>
  <reference>
    <citation>Lorén V, Manyé J, Fuentes MC, Cabré E, Ojanguren I, Espadaler J. Comparative Effect of the I3.1 Probiotic Formula in Two Animal Models of Colitis. Probiotics Antimicrob Proteins. 2017 Mar;9(1):71-80. doi: 10.1007/s12602-016-9239-5.</citation>
    <PMID>27832441</PMID>
  </reference>
  <reference>
    <citation>Lorenzo-Zúñiga V, Llop E, Suárez C, Alvarez B, Abreu L, Espadaler J, Serra J. I.31, a new combination of probiotics, improves irritable bowel syndrome-related quality of life. World J Gastroenterol. 2014 Jul 14;20(26):8709-16. doi: 10.3748/wjg.v20.i26.8709.</citation>
    <PMID>25024629</PMID>
  </reference>
  <reference>
    <citation>Naghibi MM, Day R, Stone S, Harper A. Probiotics for the Prophylaxis of Migraine: A Systematic Review of Randomized Placebo Controlled Trials. J Clin Med. 2019 Sep 11;8(9). pii: E1441. doi: 10.3390/jcm8091441. Review.</citation>
    <PMID>31514352</PMID>
  </reference>
  <reference>
    <citation>National Institute of Neurological Disorders and Stroke. Headache: Hope Through Research. April 2016.</citation>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 4, 2021</study_first_submitted>
  <study_first_submitted_qc>January 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 6, 2021</study_first_posted>
  <last_update_submitted>January 4, 2021</last_update_submitted>
  <last_update_submitted_qc>January 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Scripps Health</investigator_affiliation>
    <investigator_full_name>Robert A. Bonakdar, MD</investigator_full_name>
    <investigator_title>Director of Integrative Pain Management</investigator_title>
  </responsible_party>
  <keyword>Probiotics</keyword>
  <keyword>Headache Disorders</keyword>
  <keyword>Migraine Disorders</keyword>
  <keyword>Pain</keyword>
  <keyword>Digestive System Diseases</keyword>
  <keyword>Neurologic Manifestations</keyword>
  <keyword>Gut-Brain Axis</keyword>
  <keyword>Microbiome</keyword>
  <keyword>Functional Gastrointestinal Symptoms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified study data and information can be shared upon request after study completion</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>6 Months after Study Publication. Can be shared indefinitely</ipd_time_frame>
    <ipd_access_criteria>Email to PI or study director requesting data. Only secure data will be sent via a secure password protected document.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

